ABCA1 mediates release of cellular cholesterol and phospholipid to form high density lipoprotein (HDL). The three different mutants in the first extracellular domain of human ABCA1 associated with Tangier disease, R587W, W590S, and Q597R, were examined for their subcellular localization and function by using ABCA1-GFP fusion protein stably expressed in HEK293 cells.
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INTRODUCTION
Cholesterol is not catabolized in the peripheral cells and therefore mostly released and transported to the liver for conversion to bile acids to maintain cholesterol homeostasis. The same pathway may also remove cholesterol that has pathologically accumulated in the cells such as an initial stage of atherosclerosis. Assembly of high density lipoprotein (HDL) 1 particles by helical apolipoproteins with cellular lipid has been recognized as one of the major mechanisms for the cellular cholesterol release (1, 2) . The importance of this active cholesterol-releasing pathway in regulating cholesterol homeostasis became apparent by the finding that it is impaired in the cells from the patients with Tangier disease, genetic deficiency of circulating HDL (3, 4) . Mutations were identified in ATP-binding cassette transporter A1 (ABCA1) of the Tangier disease (TD)
patients (5-7), but the molecular mechanism of ABCA1 in the apolipoprotein-mediated HDL assembly remains unclear. While direct interaction between ABCA1 and apoA-I at the cell surface has been suggested on the basis of chemical cross-linking experiments (8, 9) , an indirect role of ABCA1 in the apoA-I binding to the cell was also proposed by a model that ABCA1 induces phosphatidylserine exofacial flopping to generate the microenvironment required for the docking of apoA-I at the cell surface (10) . Predominant substrates of ABCA1-mediated lipid release reaction is still to be determined for the HDL assembly reaction (11, 12) .
More than 30 mutations have been mapped in ABCA1 gene in patients with familial hypoalphalipoproteinemia (FHA) and TD (5) (6) (7) (13) (14) (15) . Many mutations have been identified in the putative first extracellular domain (ECD1) and the first nucleotide binding fold (NBF1) of
ABCA1. We and Fi tzgerald et al. recently demonstrated that ECD1 exists in the extracellular
space by introducing an epitope tag into ABCA1 ECD1 (16, 17) , and by analyzing glycosylation of truncated form of ABCA1 (18) . In order to investigate the mechanistic background for these mutations to cause dysfunction of ABCA1, we characterized function and subcellular localization of ABCA1-GFP and its TD mutants stably expressed in HEK293 cells. Three TD mutants M2:06885 -4 -(R587W, W590S, Q597R), clustered in ECD1, were examined in the present paper.
Immunostaining and confocal microscopic analysis showed that ABCA1 is mainly localized to plasma membrane (PM) where ECD1 is expected to be exposed to outside of the cell, but also in intracellular compartments to a substantial extent. The TD mutations in ECD1 resulted in distinct influence on function and subcellular localization of ABCA1. All three mutants were functionally impaired for the apoA-I-mediated HDL assembly. On the other hand, the two mutants R587W
and Q597R were only partially or scarcely localized to PM, while W590S was localized to PM as efficiently as the wild-type. Vanadate-induced nucleotide trapping was examined to elucidate the mechanism for the dysfunction in the W590S mutant.
EXPERIMENTAL PROCEDURES
Materials -Anti-GFP antibody was purchased from Santa Cruz Biotechnology. All other chemicals were obtained from Sigma, Wako Pure Chemical Industries or NacalaiTesque.
Generation of an antibody to ABCA1 ECD1 -The putative extracellular domain ECD1, amino acids 45-639 of human ABCA1, was expressed as a C-terminus His-tag fusion protein in E. coli BL21(DE3) and purified by Ni 2+ chromatography (Qiagen). A rat polyclonal antibody, generated using this His-tag fused ECD1, specifically interacted with human ABCA1 stably or transiently expressed in HEK293 cells in Western blotting (data not shown) and immunostaining ( Fig. 1 ).
Immunostaining and Fluorescence Microscopy -Cells were grown on a 35-mm glass-base dish (Iwaki). The cells were incubated with primary antibodies in PBS containing 5% skim milk.
After being washed, these cells were incubated with the fluorescent-labeled secondary antibodies.
The cells were directly viewed with 100x Plan-NEOFLUAR oil immersion objective on a Zeiss confocal microscope LSM510. on ice. The sample was analyzed by autoradiogram after electrophoresis in a 7 % SDS-polyacrylamide gel. Experiments were done in triplicate.
RESULTS
Subcelluar localization of ABCA1-GFP
In our previous paper, we have shown that the HA epitope inserted between the residues 207 and 208 of human ABCA1 was recognized by the anti-HA antibody from outside of cells (16) .
To confirm the extracellular localization of the hydrophilic domain containing the residue 207 (ECD1), non-permeabilized HEK293 cells were incubated with a rat polyc lonal antibody against the protein corresponding to amino acids 45-639 of human ABCA1 for immunostaining.
ABCA1-GFP apparently on the cell surface was visualized by the antibody, while the protein in the intracellular compartments was not (Fig. 1) . The results suggested that ABCA1-GFP was localized to PM and the intracellular compartments and the ECD1 domain of ABCA1 on PM was exposed to outside of the cells.
Effects of ECD1 mutations on subcellular localization of ABCA1-GFP
Many mutations in patients with TD and FHA have been identified in ECD1 of ABCA1, and three mutations (R587W, W590S, Q597R) cluster in the vicinity between amino acids 587 to 597 M2:06885 -7 -(20) (Fig. 2A) . In order to study the role of ECD1 domain in the HDL assembly function of ABCA1, we introduced these three TD mutations in ECD1 into ABCA1-GFP and transiently or stably expressed in HEK293. The expression levels of mutant ABCA1-GFP stably expressed in HEK293 cells were comparable to that of the wild-type ABCA1-GFP as shown later in Figures 3 and 5. Confocal-microscopic examination revealed that R587W and Q597R appeared to be localized mainly in ER and not to PM (Fig. 2B ). In contrast, W590S was localized to PM so much as the wild-type ABCA1-GFP was, though more was found with intracellular vesicles than the wild-type (Fig. 2B) . Immunostaining with the antibody against ECD1 confirmed the proper orientation of W590S (Fig. 2C ).
Glycosylation of ABCA1 -GFP
Glycosylation of the wild type ABCA1-GFP and its mutants R587W, W590S, and Q597R
was examined by the treatment with PNGaseF and Endo H (Fig. 3A) . Endo H cleaves two proximal N-acetylglucosamine residues of the high mannose type but not of the complex type, while PNGaseF cleaves sugar chains of both the high-mannose and complex types. The treatment with PNGaseF increased the electrophoretic mobilities of 280 kD ABCA1 to produce the 250 kD protein, the deglycosylated form of ABCA1-GFP. ABCA1 with TD mutations, R587W
and Q597R ABCA1-GFP, were sensitive to EndoH to produce the deglycosylated form of ABCA1-GFP, while the wild-type ABCA1-GFP was little digested by EndoH. These results indicated that R587W and Q597R ABCA1-GFP did not contain complex oligosaccharides and supported the confocal microscopy observation, which suggested the localization of these two TD mutants in ER or the cis-Golgi complex. On the other hand, W590S ABCA1-GFP was resistant
to Endo H, indicating that it does not contain high mannose oligosaccharides but contains complex oligosaccharides and reached the trans-Golgi complex.
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Effects of ECD1 mutations on apoA-I-mediated cholesterol release
To analyze the functional consequences of these mutations, apoA-I-mediated release of cholesterol and choline-phospholipid was examined from the stable transformants (Fig. 4AB ).
The wild-type ABCA1-GFP exported 0.14 ± 0.01 µg and 1.14 ± 0.07 µg cholesterol from cells grown in 6-well plate in the absence and presence of apoA-I, respectively, and 1.99 ± 0.25 µg and 5.88 ± 0.13 µg choline-phospholipids, respectively, to generate HDL in the medium by reducing about 15 % of cell cholesterol. The R587W mutation resulted in the apoA-I-mediated release of cholesterol and choline-phospholipids to 24 % and 23 % of the wild-type ABCA1-GFP, respectively. The Q597R mutant almost completely lost this activity. The results were apparently consistent with the inefficient localization to the cell surface of ABCA1-GFP with these mutations. The apoA-I-mediated release of cholesterol and choline-phospholipids from HEK293 expressing W590S ABCA1-GFP were 7.4 % and 13 %, respectively, of those expressing the wild-type ABCA1-GFP, although W590S ABCA1-GFP was localized to PM as efficiently as the wild-type. The apoA-I-mediated release of cellular cholesterol and choline-phospholipids was also examined with HEK293 transiently expressing the wild-type and mutant ABCA1-GFPs (Fig. 4CD) . The results were similar to those observed with the stable transformants shown in Fig. 4AB .
Interaction of ABCA1-GFP with 8-azido-[α -32 P]-ATP
To elucidate the mechanism for the loss of function of ABCA1 in W590S mutant, we examined interaction of ABCA1-GFP with ATP. Among membrane proteins of the cells expressing the wild type ABCA1-GFP, a 280-kDa protein was specifically photoaffinity-labeled with ATP (Fig. 5A, lane 7) while no protein was labeled in the untrasfected HEK293 cells (lane 5).
The mobility of the photoaffinity-labeled membrane protein in SDS-PAGE was identical to that of the wild type ABCA1-GFP visualized in western blotting (Fig. 5B, lane 1) . The photoaffinity M2:06885 -9 -labeling was negative when the samples were incubated in the absence of Mg 2+ (Fig. 5A, lane 3 (Fig. 5A, lanes 11 and 12) . These results suggested that MnATP was hydrolyzed at NBFs of ABCA1 and a stable inhibitory complex ABCA1-MnADP-Vi was formed during ATP hydrolysis cycle.
To determine whether W590S mutation affects the ATP hydrolysis cycle of ABCA1, vanadate-induced nucleotide trapping in W590S ABCA1-GFP was examined in the presence of Mn 2+ (Fig. 5C ). Membrane proteins from HEK293 cells expressing a similar amount of wild type ABCA1 or W590S ABCA1-GFP ( This suggests that the first catalytic reaction to form a stable inhibitory complex ABCA1-MnADP-Vi is not impaired by the mutation. It has been reported that apoA-I does not
properly interact with ATP hydrolysis mutants of ABCA1 (10), and that apoA-I can be interacted with ABCA1-W590S as with the wild-type ABCA1 (17, 35) . These results suggest that W590S
ABCA1-GFP possesses, at least, minimum ATPase activity, which supports apoA-I binding. 
